Stock Track | ImmunityBio Soars 5.12% as VA Hospital Begins Administering Anktiva® for Bladder Cancer

Stock Track

Aug 11, 2025

ImmunityBio, Inc. (IBRX) stock is soaring 5.12% in intraday trading on Monday, following an announcement that Houston's Michael E. DeBakey VA Medical Center has become one of the first VA hospitals to administer Anktiva® to bladder cancer patients.

The company revealed early Monday that the Houston VA facility has started using Anktiva®, ImmunityBio's innovative treatment for bladder cancer. This marks a significant milestone for the company, as it represents the beginning of Anktiva®'s integration into the extensive VA healthcare system. The VA serves millions of veterans across the United States, potentially opening up a substantial market for ImmunityBio's flagship product.

Investors are reacting positively to this news, seeing it as a strong indicator of Anktiva®'s growing acceptance and potential for widespread adoption. As one of the first VA hospitals to administer the treatment, the Michael E. DeBakey VA Medical Center could pave the way for other VA facilities to follow suit. This development could significantly boost ImmunityBio's revenue streams and market presence in the oncology sector, explaining the enthusiastic market response and the subsequent surge in the company's stock price.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1109493473"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1109493473\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1109493473?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-11 22:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1109493473","market":"nz","top_or_hot":-1,"title":"Stock Track | ImmunityBio Soars 5.12% as VA Hospital Begins Administering Anktiva® for Bladder Cancer","media":"Stock Track","content":"<p>ImmunityBio, Inc. (IBRX) stock is soaring 5.12% in intraday trading on Monday, following an announcement that Houston's Michael E. DeBakey VA Medical Center has become one of the first VA hospitals to administer Anktiva® to bladder cancer patients.</p>\n\n<p>The company revealed early Monday that the Houston VA facility has started using Anktiva®, ImmunityBio's innovative treatment for bladder cancer. This marks a significant milestone for the company, as it represents the beginning of Anktiva®'s integration into the extensive VA healthcare system. The VA serves millions of veterans across the United States, potentially opening up a substantial market for ImmunityBio's flagship product.</p>\n\n<p>Investors are reacting positively to this news, seeing it as a strong indicator of Anktiva®'s growing acceptance and potential for widespread adoption. As one of the first VA hospitals to administer the treatment, the Michael E. DeBakey VA Medical Center could pave the way for other VA facilities to follow suit. This development could significantly boost ImmunityBio's revenue streams and market presence in the oncology sector, explaining the enthusiastic market response and the subsequent surge in the company's stock price.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | ImmunityBio Soars 5.12% as VA Hospital Begins Administering Anktiva® for Bladder Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | ImmunityBio Soars 5.12% as VA Hospital Begins Administering Anktiva® for Bladder Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-08-11 22:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ImmunityBio, Inc. (IBRX) stock is soaring 5.12% in intraday trading on Monday, following an announcement that Houston's Michael E. DeBakey VA Medical Center has become one of the first VA hospitals to administer Anktiva® to bladder cancer patients.</p>\n\n<p>The company revealed early Monday that the Houston VA facility has started using Anktiva®, ImmunityBio's innovative treatment for bladder cancer. This marks a significant milestone for the company, as it represents the beginning of Anktiva®'s integration into the extensive VA healthcare system. The VA serves millions of veterans across the United States, potentially opening up a substantial market for ImmunityBio's flagship product.</p>\n\n<p>Investors are reacting positively to this news, seeing it as a strong indicator of Anktiva®'s growing acceptance and potential for widespread adoption. As one of the first VA hospitals to administer the treatment, the Michael E. DeBakey VA Medical Center could pave the way for other VA facilities to follow suit. This development could significantly boost ImmunityBio's revenue streams and market presence in the oncology sector, explaining the enthusiastic market response and the subsequent surge in the company's stock price.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IBRX","symbol_name":"ImmunityBio, Inc.","start_time":0,"source_url":"","article_id":"1109493473","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1109493473","pubTimestamp":1754921552,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"ImmunityBio, Inc. (IBRX) stock is soaring 5.12% in intraday trading on Monday, following an announcement that Houston's Michael E. DeBakey VA Medical Center has become one of the first VA hospitals...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IBRX":"ImmunityBio, Inc."},"translate_title":"个股追踪|随着VA医院开始给药Anktiva，ImmunityBio飙升5.12%®用于膀胱癌","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBRX":1},"content_text":"ImmunityBio, Inc. (IBRX) stock is soaring 5.12% in intraday trading on Monday, following an announcement that Houston's Michael E. DeBakey VA Medical Center has become one of the first VA hospitals to administer Anktiva® to bladder cancer patients.\nThe company revealed early Monday that the Houston VA facility has started using Anktiva®, ImmunityBio's innovative treatment for bladder cancer. This marks a significant milestone for the company, as it represents the beginning of Anktiva®'s integration into the extensive VA healthcare system. The VA serves millions of veterans across the United States, potentially opening up a substantial market for ImmunityBio's flagship product.\nInvestors are reacting positively to this news, seeing it as a strong indicator of Anktiva®'s growing acceptance and potential for widespread adoption. As one of the first VA hospitals to administer the treatment, the Michael E. DeBakey VA Medical Center could pave the way for other VA facilities to follow suit. This development could significantly boost ImmunityBio's revenue streams and market presence in the oncology sector, explaining the enthusiastic market response and the subsequent surge in the company's stock price.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}